Company Filing History:
Years Active: 2024
Title: Laura Kapitza: Innovator in Targeted T Cell Therapy
Introduction
Laura Kapitza is a prominent inventor based in Bergisch Gladbach, Germany. She has made significant contributions to the field of immunology, particularly in the development of targeted therapies for T cells. Her innovative work has led to the creation of a unique patent that enhances the precision of T cell targeting.
Latest Patents
Laura Kapitza holds a patent for a "CD62L specific lentiviral vector particle for targeted transduction of T cell subsets." This invention provides a composition that includes a pseudotyped retroviral vector particle. The vector particle comprises an envelope protein with antigen-binding activity, which is crucial for targeting T cells expressing CD62L. This advancement has the potential to improve therapeutic strategies in immunotherapy.
Career Highlights
Laura is currently employed at Miltenyi Biorec B.V. Co., Kg, where she continues to push the boundaries of research in cellular therapies. Her work is characterized by a commitment to innovation and excellence in the field of biotechnology.
Collaborations
Throughout her career, Laura has collaborated with notable colleagues, including Thomas Schaser and Andrew Kaiser. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking technologies.
Conclusion
Laura Kapitza's contributions to targeted T cell therapy exemplify the impact of innovative thinking in biotechnology. Her patent and ongoing work at Miltenyi Biorec highlight her role as a leader in the field.